MGMT
|
Hyper
|
88 OPSCC
|
Poorer PFS and OS
|
[45]
|
ALDH3A1
|
Hyper
|
76 HNSCC, including 15 OPSCC
|
Decreased OS
|
[172]
|
TAP1
|
Hyper
|
SMG1
|
Hypo
|
40 OPSCC
|
Improved OS in HPV-positive OPSCC
|
[153]
|
ALDH1A2
|
Hypo
|
170 OPSCC (3 independent cohorts)
|
Improved clinical outcome in HPV-positive OPSCC
|
[154]
|
GATA4
|
Hyper
|
GRIA4
|
Hyper
|
IRX4
|
Hyper
|
OSR2
|
Hypo
|
DAPK1
|
Hyper
|
70 HNSCC, including 9 OPSCC
|
Lymph node metastasis
|
[173]
|
MGMT
|
Hyper
|
WIF1
|
Hyper
|
43 HNSCC, including 19 OPSCC
|
Decreased OS
|
[54]
|
GALR1/2
|
Hyper
|
202 HNSCC, including 58 OPSCC
|
Poor survival with the highest association in HPV-negative OPSCC
|
[174]
|
LINE-1
|
Hypo
|
110 OPSCC (2 independent cohorts)
|
Increased risk of early relapse in HPV-negative OPSCC
|
[60]
|